SEC Comment Letter for CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689) (CBIO) — May 23, 2019
CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689)
Date: May 23, 2019 · CIK: 0001253689 · Accession: 0000000000-19-008876
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231577
Letter
May 23, 2019 Rachel K. King Chief Executive Officer Glycomimetics, Inc. 9708 Medical Center Drive Rockville, MD 20850 Re:Glycomimetics Inc. Registration Statement on Form S-3 Filed May 17, 2019 File No. 333-231577 Dear Ms. King: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Brian F. Leaf, Esq.
Show Raw Text
May 23, 2019
Rachel K. King
Chief Executive Officer
Glycomimetics, Inc.
9708 Medical Center Drive
Rockville, MD 20850
Re:Glycomimetics Inc.
Registration Statement on Form S-3
Filed May 17, 2019
File No. 333-231577
Dear Ms. King:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Brian F. Leaf, Esq.